Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.

Détails

Ressource 1Télécharger: fimmu-07-00573.pdf (4801.34 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_65B45F9B7588
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.
Périodique
Frontiers in immunology
Auteur⸱e⸱s
Murray T., Fuertes Marraco S.A., Baumgaertner P., Bordry N., Cagnon L., Donda A., Romero P., Verdeil G., Speiser D.E.
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
7
Pages
573
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
A major limiting factor in the success of immunotherapy is tumor infiltration by CD8(+) T cells, a process that remains poorly understood. In the present study, we characterized homing receptors expressed by human melanoma-specific CD8(+) T cells. Our data reveal that P-selectin binding and expression of the retention integrin, very late antigen (VLA)-1, by vaccine-induced T cells correlate with longer patient survival. Furthermore, we demonstrate that CD8(+)VLA-1(+) tumor-infiltrating lymphocytes (TILs) are highly enriched in melanoma metastases in diverse tissues. VLA-1-expressing TIL frequently co-express CD69 and CD103, indicating tissue-resident memory T cells (TRM) differentiation. We employed a mouse model of melanoma to further characterize VLA-1-expressing TIL. Our data show that VLA-1(+) TRM develop in murine tumors within 2 weeks, where they exhibit increased activation status, as well as superior effector functions. In addition, in vivo blockade of either VLA-1 or CD103 significantly impaired control of subcutaneous tumors. Together, our data indicate that VLA-1(+) TRM develop in tumors and play an important role in tumor immunity, presenting novel targets for the optimization of cancer immunotherapy.
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/01/2017 19:07
Dernière modification de la notice
21/11/2022 8:28
Données d'usage